30 closest matches · ranked by relevance
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Pharmacodynamics · Healthy Subjects
Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…
Acute Coronary Syndrome
Primary: Adverse Events of LC23-1306
Healthy
Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…
Healthy
Primary: Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of…
Healthy
Primary: Fraction of [14C]-Radioactivity Excreted in Urine as Percentage of the Administered Oral Dose Over the Time Interval From 0 to the Last Quantifiable Time Point…
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
Healthy Volunteers
Primary: Mass Balance Recovery of Total Radioactivity: CumAe (Urine) — 70.9 mg equiv
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 0; 12.5; 25.0; 37.5 Percentage of participants
Aging · Insulin Resistance
Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events — 16.7; 16.7; 33.3; 0.0 percentage of participants
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
NASH With Fibrosis
Primary: To Determine the Mass Balance Recovery After a Single Oral Dose of [14C]-Rencofilstat — 91 percentage of total radioactivity
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Hypertension
Primary: Number of Participants Who Experienced One or More Adverse Events — 2; 3; 5; 2 Participants
Contraception · Hypogonadism
Primary: Area Under the Curve-Serum T — 143; 198; 144; 384 nmol*h/L — p=<0.05
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Schizophrenia
Primary: Physical Examination Shift Table — 1; 1; 0; 0 Participants abnormal at end of study
Healthy
Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-tz) — 34.3 Percentage of administered dose (%)
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Healthy
Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-t2) — 48.1 Percentage of dose excreted (%)
Pharmacokinetics · Tolerability
Primary: Pharmacokinetics — 11.0 ng/dL
Alzheimer Disease
Primary: Plasma CT1812 Concentration at 96 Hours Timepoint — 0.0000707 μg/mL
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of BI 1358894 Over the Time Interval From 0 to Infinity After i.v. Administration and After Oral Administration…
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 6.7; 50.0; 33.3; 0.0 Percentage of participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 0; 0; 1 participants
Hypogonadism, Male
Primary: Change From Baseline in 24-hour Average Ambulatory Systolic Blood Pressure After 120 Days Treatment — 128.9; 130.6; 1.7 mmHg
Hypogonadism
Primary: Cmax-am for Oral TU Across Breakfast With Varying Fat Content — 250.7; 334.7; 529.7; 506.0 ng/dL